BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 32 CNY 3.59% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

BrightGene Bio-Medical Technology Co Ltd
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BrightGene Bio-Medical Technology Co Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Total Assets
ÂĄ5B
CAGR 3-Years
40%
CAGR 5-Years
42%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Assets
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Assets
ÂĄ17B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Assets
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Assets
ÂĄ54.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Assets
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is BrightGene Bio-Medical Technology Co Ltd's Total Assets?
Total Assets
5B CNY

Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's Total Assets amounts to 5B CNY.

What is BrightGene Bio-Medical Technology Co Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
42%

Over the last year, the Total Assets growth was 8%. The average annual Total Assets growth rates for BrightGene Bio-Medical Technology Co Ltd have been 40% over the past three years , 42% over the past five years .

Back to Top